Bristol-Myers: FDA approves Opdivo for lung cancer
(CercleFinance.com) - US health regulators have approved Bristol-Myers Squibb's immunotherapy Opdivo for patients with late-stage small cell lung cancer who fail to respond to other therapies.
The drug has received approval from the US Food and Drug Administration (FDA) as the first and only immuno-oncology treatment for metastatic small-cell lung cancer whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy.
Opdivo has been granted priority review from the FDA in this indication, which is one of two main types of lung cancer, and which accounts for about 10% to 15% of all lung cancers.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The drug has received approval from the US Food and Drug Administration (FDA) as the first and only immuno-oncology treatment for metastatic small-cell lung cancer whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy.
Opdivo has been granted priority review from the FDA in this indication, which is one of two main types of lung cancer, and which accounts for about 10% to 15% of all lung cancers.
Copyright (c) 2018 CercleFinance.com. All rights reserved.